Nanovibronix Inc
NASDAQ:NAOV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (23), the stock would be worth $-300.02 (7 853% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.3 | $3.87 |
0%
|
| Industry Average | 23 | $-300.02 |
-7 853%
|
| Country Average | 23.2 | $-302.48 |
-7 916%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Nanovibronix Inc
NASDAQ:NAOV
|
4.2m USD | -0.3 | -0.8 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.5B USD | 62.8 | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
157.7B USD | 21.5 | 25.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 30.7 | 37.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
103.9B USD | 22.8 | 22.5 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
85.4B USD | 25.9 | 24 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 33.6 | 44.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 20.9 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 43.2 | 42.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.4B USD | 22.3 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.1B USD | 16.9 | 21 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.4 |
| Median | 23.2 |
| 70th Percentile | 35.1 |
| Max | 3 178 983.5 |
Other Multiples
Nanovibronix Inc
Glance View
NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The company is headquartered in Elmsford, New York and currently employs 12 full-time employees. The company went IPO on 2015-04-24. The firm is focused on developing noninvasive biological response-activating devices utilizing its low intensity surface acoustic wave (SAW) technology, which targets biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products, which are in various stages of clinical and market development consist of UroShield, PainShield and WoundShield. Its PainShield family of products include PainShield MD, PainShield Plus and PainShield Relief. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low frequency, low intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. Its wholly owned subsidiary is NanoVibronix Ltd.
